Thus, the practice of frequentist inference revolves around quantifying the probability of 107 incorrectly classifying a person given their test result.
108
For clinical applications, there are at least three major problems with the frequentist 109 approach. First, for most people frequentist probabilities are not a natural way to reason.
110
For individual patients, a clinician wants to know the probability that a patient has a par-111 ticular disease; at best, a standard frequentist analysis only computes the probability that 112 the patient is misclassified as diseased. Second, since frequentist statistics generally find 113 the probability of sample extremeness, reasoning with frequentist statistics is most natural 114 and convenient with dichotomous cutoffs (e.g. disease and not disease) [26] . Therefore, biomarkers. Third, frequentist inference eliminates the possibility of easily defining a prior 120 probability [31] . Certainly a 60 year-old HIV patient with a CD4 count of 50 cells/mL, with 121 a 100 pack-year smoking history, and a viral load of 100, 000 copies/mL on no prophylaxis is 122 not at the same risk for pneumonia as a 30 year-old with CD4 count of 700 cells/mL, with 123 no smoking history, and an undetectable viral load. Therefore, even though it is compar-124 atively easy to calculate empirical prior probabilities for many diseases, incorporating that 125 information is essentially impossible.
126
By contrast, a Bayesian statistical approach easily answers all of these challenges. First,
127
Bayesian probabilities are the natural way that humans reason. Clinicians always implicitly 128 begin with a prior probability of disease [31] . In fact, the practice of building and ranking 129 a differential diagnosis is founded on the Bayesian principle of prior probability. Next,
130
clinicians perform a test and subsequently update their degree of belief that a patient has a 131 particular disease [27, 28, 31] . Mathematically, a likelihood ratio is the most convenient means 132 to update the probability of disease [31] . Although most Bayesian analyses of biomarker tests 133 fall into the same dichotomous trap as their frequentist contemporaries, that is certainly not 134 necessary or particularly helpful. One can calculate likelihood ratios for every possible test 135 result, and those continuous likelihood ratios can be used to update the pretest probability of 136 disease for individual patients [26, 27, 29] . Then, clinicians are left with a simple, interpretable 137 probability that represents the probability of disease.
138
In this study, I find that CRP, PCT, and lytA can all independently aide in the diagnosis 139 of pneumococcal pneumonia, but they cannot be combined to produce improved results. In 140 addition, the current cut points for each test do not optimize their discriminatory power.
141
According to the best traditional method and a more modern Bayesian approach, the cutoffs 142 should be increased for etiology determination. Nevertheless, optimizing the cutoff is prob- 
Methods

152
The data used in this study was collected and analyzed previously in a separate manner [22] .
153
I downloaded the data from Data Dryad [32] . The data included a total of 280 HIV infected 154 patients. Patients were admitted to the study after having a confirmatory chest x-ray for 155 community acquired pneumonia. There were many available predictors in the dataset includ-
156
ing age, Bartlett score, CD4 count, Bactrim prophylaxis status (either taking or not taking), copeptin, procalcitonin, C-reactive protein, and bacteremia. In addition, there were three response variables including bacteremia (either bacteremic or not bacteremic), pneumococ- PCT, and lytA in all pairwise combinations as predictors in a multivariate logistic model.
177
Age was not a significant predictor, and I therefore eliminated it from all subsequent analyses.
178
Statistical significance in multivariate regression was established with the p−value of each 179 predictor variable. Next, I computed the sensitivity and specificity for every predictor value 180 in the dataset. The sensitivity and specificity were computed as
where x represents each biomarker value. Thus, T P x is the number of true positives at x,
182
F P x is the number of false positives at x, T N x is the number of true negatives at x, and
183
F N x is the number of false negatives at x. I calculated the Youden index [24, 25] J(x) = (sensitivity x + specif icity x − 1),
where J is the Youden J index. For the standard method, I found the ideal cutoff value for 186 each biomarker as the biomarker value, x, that maximized the Youden J(x).
187
The transition to Bayesian statistics required computing several additional quantities [31] .
188
The easiest and most extensible approach for clinical decision-making involves the use of 189 likelihood ratios to update the probability of disease after administering a clinical test [31] .
190
In an effort to compute likelihood ratios over the range of data with relatively smooth resulted from the relatively small boundary sample size.
194
I started by calculating the empirical pretest probability in the dataset as the prevalence 195 of pneumococcal disease. Then, the LR+ and LR− were calculated with a simple ratio of 196 sensitivity and specificity relations:
where x again is every value of each biomarker. The associated confidence interval was 198 calculated in accordance with [40] as
where 1 − α is the standard confidence level and
At first glance, this notation may seem overly formal. However, the ξ 1− 
Finally, the optimal cutoff value of a biomarker is simply the test value that maximizes the 209 difference in the two posttest probabilities.
210
Next, I proceeded to calculate the continuous likelihood ratio by two different means. In 211 the first, I used the methodology of Simel et al. [26] . This method requires first fitting a 212 logistic model [27] , then computing the likelihood ratio using the logistic parameters. Thus, I used the logistic probability function, 
where p is the pretest probability of the relevant condition. In this case, I used the empir- 
which could be further simplified into a quadratic form utilizing only T P x , F P x , T N x , and probability to obtain the plotted posttest probabilities.
232
An accompanying website to compute the posttest probability of pneumococcal infec-233 tion is available: http://meyerapps.org/pneumococcal_etiology_hiv. Code and data
234
for the web application are freely available on Github: https://github.com/ausmeyer/ 235 pneumococcal_etiology_hiv. I built the website using the shiny server framework and the
236
plotly interactive plotting library [41, 42] .
237
Results
238
Biomarkers can help to identify S. pneumoniae etiology
239
Univariate logistic regression revealed that only three of the predictive biomarkers had a 240 strong connection with pneumococcal etiology (Fig. 1 ). These three were C-reactive pro- specificity for each available test value in the dataset (Fig. 2) . For CRP, the established "nor-253 mal" range is generally less than 3 mg/dL or less than 10 mg/dL for some high sensitivity 254 tests. By contrast, I found an equivalence point between 20 mg/dL and 22.5 mg/dL where 255 the sensitivity and specificity were both above 75%. In the CRP "normal" range, the speci-256 ficity to diagnose pneumococcal pneumonia approached zero. Similarly for procalcitonin,
257
there was equivalence near 2 ng/mL where both sensitivity and specificity were approxi-258 mately 75%, which is far above the normal cutoff of 0.5 ng/mL. For lytA, I again found 259 an equivalence point at approximately 4.5 log 10 copies/mL with a similar sensitivity and 260 specificity. Thus, plotting sensitivity and specificity suggested the same conclusion as that 261 from logistic regression; each of the tests provided similar value in diagnosing pneumococcal 262 pneumonia. However, a different statistic is required to identify the ideal cutoff. Standard approach to identify a cutoff value for S. pneumoniae As expected, it was difficult to find the ideal dichotomous cutoff by ROC alone. Therefore,
268
I computed the Youden index and plotted it both against the traditional false positive rate 269 and against the more useful biomarker concentration (Fig. 3) . According to the Youden 270 index, the optimal false positive rate for CRP was 0.3 and the optimal biomarker cutoff was 271 16.67 mg/dL. For procalcitonin, the optimal dichotomous false positive rate was 0.34 and the 272 optimal biomarker cutoff was 2.22 ng/mL. For lytA, the optimal false positive cutoff was 0.27 273 and the optimal concentration was 4.47 log 10 copies/mL or 2.95×10 4 copies/mL. Each cutoff 274 was significantly higher than that used to diagnosis anything in the HIV-uninfected popula- show the optimal dichotomous cutoff for each biomarker. The optimal value for C-reactive protein is 16.67 mg/dL, for procalcitonin is 2.22 ng/mL, and for lytA is 4.47 log 10 copies/mL or 2.95 × 10 4 copies/mL. By Youden index, any value of lytA less than 5 log 10 copies/mL or 10 5 copies/mL is essentially identical.
Bayesian approach to identify the optimal cutoff value
In contrast to the standard approach that focuses on applying various statistical tests with 280 a probability of incorrectness, a Bayesian approach couches the problem itself in terms of 281 probabilities. Thus, every question to be answered requires a prior probability. In clinically-
282
oriented statistics, the prior probability is often the disease prevalence in the naïve case or the 283 pretest probability when more information is available. With a pretest probability, Bayesian confidence interval for each biomarker (Fig. 4) . The three biomarkers all had an extensive 291 range where the confidence band did not overlap one, which implies statistical significance.
292
The lytA biomarker displayed the longest and most valuable range of likelihood ratio neg- In black dash, I show the y = 1 line. The limited sample size for C-reactive protein make it difficult to assess the upper limit. The traditional cutoff for procalcitonin = 0.5 ng/mL may need to be adjusted upward to improve clinical yield. The cutoff of lytA = 8×10 3 copies/mL may be lower than ideal; the primary value of lytA compared to procalcitonin is in lytA's negative predictive value. For PCT, LR− would be maximized nearer the lower detectable limit with little loss in positive predictive value.
Rather than the Youden J index, Bayesian statistics suggests a very different manner 303 of identifying the optimal dichotomous cutoff. From a Bayesian perspective, the value of a 304 particular cutoff on a clinical test is most directly understood as the maximum difference 305 between the posttest probability after a postive test and the posttest probability after a 306 negative test. Thus, the most valuable test is the one that most dramatically moves the 307 posttest probability.
308
I used the pretest probability in the sample along with the LR+ and LR− to plot the 309 predicted posttest probabilities for every possible cutoff in the data (Fig. 5) . If the cutoff were 310 set to a point on the x-axis, any positive test for that cutoff had the plotted posttest positive 311 probability and any negative test had the plotted posttest negative probability. Then, to find 312 the optimal cutoff I subtracted the posttest negative probability from the posttest positive 313 probability. In dramatic contrast to the Youden index, this calculation showed that the vast 314 majority of available cutoffs were essentially identical. For CRP, although the optimal value 315 was 30.6 mg/dL, any value greater than 10 mg/dL produced a similar posttest probability 316 difference. Likewise for PCT, the optimal cutoff was 17.4 ng/mL, but cutoffs up to 40 ng/mL 317 were similarly informative. Interestingly, the optimal cutoff for lytA was exactly the same 318 value as that found by the Youden index, 4.47 log 10 copies/mL or 2.95 × 10 4 copies/mL. lytA density (log10 copies/mL) posttest probability diff optimal cutoff probability difference F Figure 5 : Probability plots for each biomarker. In A, I show the posttest probability calculations for C-reactive protein. In B, I show the posttest probability calculations for procalcitonin. In C, I show the posttest probability calculations for lytA. In D, I show the difference between the positive posttest probability and negative posttest probability for Creactive protein. In E, I show the difference between the positive posttest probability and negative posttest probability for procalcitonin. In F, I show the difference between the positive posttest probability and negative posttest probability for lytA. In red dash, I show the pretest probability. In terms of Bayesian information, the ideal dichotomous cutoff is that value that maximizes the difference between the positive posttest probability and the negative pottest probability. Thus, the optimal cutoff for C-reactive protein is 30.6 mg/dL, for procalcitonin is 17.4 ng/mL, and for lytA is 4.47 log 10 copies/mL or 2.95 × 10 4 copies/mL. The optimal cutoff of lytA by Bayesian yield is almost identical to that by Youden index. However, as with Youden index, any value less than 5 log 10 copies/mL is essentially identical. In addition, by Bayesian yield there is no clear ideal value for any biomarker; many values perform similarly well.
Quantitative likelihood ratios improve probability calculations lytA density (log10 copies/mL) likelihood ratio C Figure 6 : Continuous likelihood ratios for several pretest probabilities [26] . In A, I show the likelihood ratios for C-reactive protein with the actual pretest probability in the data. In B, I show the likelihood ratios for procalcitonin with the actual pretest probability in the data. In C, I show the likelihood ratios for lytA with the actual pretest probability in the data. The dashed line is the uninformative likelihood ratio at LR = 1. lytA density (log10 copies/mL) probability pneumococcal pretest combined continuous I Figure 7 : Posttest probability calculations using combined likelihood scores. In A, I show the calculated posttest probability combining the LR+ and LR− values at each point for C-reactive protein. In B, I show the calculated posttest probability combining the LR+ and LR− values at each point for procalcitonin. In C, I show the calculated posttest probability combining the LR+ and LR− values at each point for lytA. In D, I show the calculated posttest probability using the continuous LR values for C-reactive protein. In E, I show the calculated posttest probability using the continuous LR values for procalcitonin. In F, I show the calculated posttest probability using the continuous LR values for lytA. In G, I show A and D overlay to display their correlation. In H, I show B and E overlay to show their correlation. In I, I overlay C and F to show their correlation. The bottom row shows that one can empirically calculate posttest probability without the need for logistic regression. In red dash, I show the pretest probability of pneumococcal infection.
In terms of clinical utility, my analysis showed that CRP and lytA were broadly capable 339 of making a pneumococcal diagnosis either highly likely or highly unlikely. A CRP test result of less than 5 mg/dL meant the posttest probability of pneumococcal etiology was 341 less than 15%. That was also the case for lytA values of less than 2.5 log 10 copies/mL. On x-ray confirmed pneumonia in HIV patients.
373
Although there are a number of prior studies that evaluate the value of various biomarkers 374 in the diagnosis and treatment of pneumonia, relatively few use biomarkers to help diagnose a 375 particular infectious etiology. Furthermore, almost none give concrete guidance to clinicians 376 regarding the posttest probability of a particular organism. In most cases, investigators note 377 a "statistically significant" difference in the distribution of test results between healthy and 378 diseased populations. For example, many papers suggest CRP [8, 11] and PCT [11, [13] [14] [15] [16] [17] 379 can add value to either the diagnosis or treatment of a wide range of ailments. Specifically,
380
PCT can shorten the duration of clinical treatment and improve time-to-treatment. I found 381 only one paper where PCT proved capable of distinguishing between typical and atypical 382 pneumonia [13] . By contrast, there are several studies showing that lytA can differentiate 383 pneumococcal from non-pneumococcal pneumonia [22] . Unfortunately, beyond suggesting a 384 single dichotomous cutoff, none of those studies provide information regarding the proba-385 bility of S. pneumoniae infection. Therefore, they fail to answer the most relevant clinical 386 question... with this test result, how much more or less likely is S. pneumoniae infection?
387
Even in studies where the relative risk is calculated, the inability to incorporate a pretest 388 probability into the relative risk ratio means that the accuracy of posttest estimation is case, the investigator defines more than a single cutoff to produce several ordinal categories 415 [28] [29] [30] . Such an approach is most useful when the data itself is ordinal (e.g. a pain scale types. In such cases, investigators can calculate a likelihood ratio for each possible test result.
421
Although there is at least one existing approach to make such a computation, it requires 422 first fitting a logistic regression curve and subsequently using coefficients of the fit. Although 423 that approach may be relatively simple for biostatistics professionals, it is far from obvious 424 how it may be applied more broadly. More importantly, the logistic function itself makes 
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